> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Advisory Panel to Mull Device Metal Hypersensitivity
- URL: https://www.fdaweb.com/advisory-panel-to-mull-device-metal-hypersensitivity/
- Published: 2019-03-15T12:00:00.000Z
- Updated: 2026-09-15T01:13:04.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5143624

FDA says that this fall it plans to hold an advisory committee meeting to discuss nitinol and other metals in device implants to understand the potential risk for certain patients with hypersensitivity or exaggerated immune and inflammatory reactions to the metals. “We’ve been exploring the link between immune and inflammatory markers and symptoms such as pain, headaches and fatigue in patients who have these devices implanted,” an [agency notice](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633602.htm?ref=fdaweb.com) says. Prior to the meeting, FDA will release a peer-reviewed white paper that will summarize the current scientific knowledge regarding different aspects of metal implants, including how the structure and function of these devices are impacted by the body’s tissues, muscles and blood supply and how the metal components dissolve and interact with immune cells.

This committee meeting is part of FDA’s ongoing effort to advance the evaluation of materials used in implantable devices. The panel will seek expert input on what relevant scientific information the agency should solicit from manufacturers to be considered in both premarket review and postmarket surveillance. “Importantly, we'd like to determine how to identify patients who might be at increased risk of having a hypersensitivity response before they receive a metal implant, so they can consider those risks along with the device’s benefits,” FDA says. Additionally, the panel will to determine what studies are needed to further understand the extent immune/inflammatory responses to certain metals contribute to device-related adverse events and steps to mitigate potential risks.

“Enhancing our collective understanding of materials science could lead to identifying materials that may cause an exaggerated response in sensitive individuals and advance the development of safer materials,” FDA says. “Development of new tests to identify at-risk patients would help ensure they do not receive implantable devices that contain the material to which they are sensitive, therefore further enhancing patient safety and advance a precision medicine approach to the selection of device interventions.”